Sport Investors League
  • Politics
  • Stocks
  • Investing
  • Business

Sport Investors League

  • Politics
  • Stocks
  • Investing
  • Business
Investing

Radiopharm Theranostics Targets Nasdaq Listing by End of 2024

by admin July 26, 2024
July 26, 2024
Radiopharm Theranostics Targets Nasdaq Listing by End of 2024

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced it expects to obtain a secondary listing on the Nasdaq Capital Market by the end of 2024.

As announced on 14 February 2023, the Company initiated the process to obtain a secondary listing on the Nasdaq Capital Market. Due to market conditions, the Company subsequently delayed the process.

As announced on 25 June 2024, as part of a A$70 million capital raising, the Company agreed with certain US institutional investors to seek a listing of its ordinary shares in the form of American Depositary Shares on Nasdaq by the end of 2024.

Yesterday the Company filed an amendment to its registration statement on Form 20-F with the US Securities and Exchange Commission (SEC) and is continuing to progress a listing application with Nasdaq. The Company expects the SEC and Nasdaq to complete their respective review processes by late August and, when their processes are successfully completed, then the listing on Nasdaq would occur.

The Nasdaq listing will take the form of a Level 2 American Depositary Receipt program, with each American Depositary Share representing 200 ordinary shares, and will not involve the raising of any capital. The American Depositary Shares (ADS) are expected to trade on Nasdaq under the ticker RADX. Deutsche Bank Trust Company Americas will be appointed by the Company as depositary, custodian and registrar of the ADS.

The Nasdaq listing will complement the existing primary listing of RAD shares on the Australian Securities Exchange (ASX) with minimal additional administration. Ordinary shares are currently listed on the ASX under the RAD symbol where they will continue to trade following the Nasdaq listing.

‘We are confident that obtaining a listing on Nasdaq will complement our loyal existing Australian shareholder base by expanding Radiopharm’s access to investors globally, and thereby drive increased shareholder value with enhanced liquidity for all shareholders,’ said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics.

This program is part of an ongoing strategy to expand the Company’s reach to US institutional and retail investors by enabling them to purchase the Company’s shares via a US stock market, in the American time zone and in US dollars.

The review process by the SEC in relation to the registration statement and by Nasdaq in relation to the listing application continues to be in progress. There can be no assurance as to the completion or timing of this process or such a listing.

Authorised on behalf of the Radiopharm Theranostics board of directors by Executive Chairman Paul Hopper.

Click here for the full ASX Release

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
Melodiol Global Health
next post
Cyprium and Glencore Announce Commercial Strategic Partnership

Related Posts

How Would a New BRICS Currency Affect the...

January 7, 2025

Elixir Energy Limited (ASX: EXR) – Trading Halt

July 23, 2024

Jindalee Lithium Limited (ASX: JLL) – Reinstatement to...

July 4, 2024

Should You Invest in Silver Bullion? (Updated 2024)

October 24, 2024

Clean Energy & Precious Metals Hybrid Investor Conference...

May 21, 2024

Precious Metals & Critical Minerals Hybrid Investor Conference...

May 17, 2025

Toyota Shares Hydrogen Roadmap, Highlighting On- and Off-Road...

March 18, 2025

John Feneck: Gold, Silver, Copper, Uranium — 10...

May 17, 2024

Top 3 Canadian Nickel Stocks of 2024

August 7, 2024

RETRANSMISSION: Group Eleven to be Featured on Radius...

May 9, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • Elon Musk halts plans for new political party, prioritizing business instead: report

      August 21, 2025
    • Ukraine’s stolen children crisis looms large as NATO meets on Russia’s war

      August 21, 2025
    • Duffy’s DOT accuses Biden, Buttigieg of inflating air traffic controller pipeline: ‘Juiced the numbers’

      August 21, 2025
    • FBI arrests woman on ‘Ten Most Wanted Fugitives’ hiding in India, transports to US for prosecution

      August 21, 2025
    • Vance, White House blast ‘crazy communists’ protesting DC clean-up, terrorizing locals: ‘Stupid White hippies’

      August 21, 2025

    Categories

    • Business (1,071)
    • Investing (2,877)
    • Politics (3,520)
    • Stocks (1,155)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sportinvestorsleague.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 sportinvestorsleague.com | All Rights Reserved